collection
MENU ▼
Read by QxMD icon Read
search

Lung cancer

shared collection
3 papers 25 to 100 followers
https://www.readbyqxmd.com/read/24399557/smoking-prevalence-and-cigarette-consumption-in-187-countries-1980-2012
#1
Marie Ng, Michael K Freeman, Thomas D Fleming, Margaret Robinson, Laura Dwyer-Lindgren, Blake Thomson, Alexandra Wollum, Ella Sanman, Sarah Wulf, Alan D Lopez, Christopher J L Murray, Emmanuela Gakidou
IMPORTANCE: Tobacco is a leading global disease risk factor. Understanding national trends in prevalence and consumption is critical for prioritizing action and evaluating tobacco control progress. OBJECTIVE: To estimate the prevalence of daily smoking by age and sex and the number of cigarettes per smoker per day for 187 countries from 1980 to 2012. DESIGN: Nationally representative sources that measured tobacco use (n = 2102 country-years of data) were systematically identified...
January 8, 2014: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/24576776/preoperative-chemotherapy-for-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis-of-individual-participant-data
#2
REVIEW
(no author information available yet)
BACKGROUND: Individual participant data meta-analyses of postoperative chemotherapy have shown improved survival for patients with non-small-cell lung cancer (NSCLC). We aimed to do a systematic review and individual participant data meta-analysis to establish the effect of preoperative chemotherapy for patients with resectable NSCLC. METHODS: We systematically searched for trials that started after January, 1965. Updated individual participant data were centrally collected, checked, and analysed...
May 3, 2014: Lancet
https://www.readbyqxmd.com/read/23835707/paramount-final-overall-survival-results-of-the-phase-iii-study-of-maintenance-pemetrexed-versus-placebo-immediately-after-induction-treatment-with-pemetrexed-plus-cisplatin-for-advanced-nonsquamous-non-small-cell-lung-cancer
#3
RANDOMIZED CONTROLLED TRIAL
Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck, Jesús Corral, Symantha Melemed, William John, Nadia Chouaki, Annamaria H Zimmermann, Carla Visseren-Grul, Cesare Gridelli
PURPOSE: In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI, 0.49 to 0.79; P < .001). Here we report final overall survival (OS) and updated safety data. PATIENTS AND METHODS: In all, 939 patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patients with no disease progression and Eastern Cooperative Oncology Group performance status 0 or 1 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 359) or placebo (n = 180)...
August 10, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"